ARK Genomic Revolution ETF (ARKG)

BATS: ARKG · IEX Real-Time Price · USD
+1.00 (3.06%)
At close: Jan 31, 2023, 4:00 PM
-0.35 (-1.04%)
Pre-market: Feb 1, 2023, 6:17 AM EST
Assets $2.19B
Expense Ratio 0.75%
PE Ratio n/a
Shares Out 67.00M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Dec 29, 2021
Payout Ratio n/a
1-Year Return -33.74%
Volume 1,055,562
Open 32.87
Previous Close 32.70
Day's Range 32.83 - 33.73
52-Week Low 26.38
52-Week High 52.47
Beta 1.45
Holdings 47
Inception Date Oct 31, 2014

About ARKG

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.

Asset Class Equity
Category Health
Region Global
Stock Exchange BATS
Ticker Symbol ARKG
Issuer Website ARK

Top 10 Holdings

50.65% of assets
Name Symbol Weight
Exact Sciences Corporation EXAS 11.66%
Pacific Biosciences of California, Inc. PACB 5.72%
Teladoc Health, Inc. TDOC 4.88%
Ionis Pharmaceuticals, Inc. IONS 4.77%
CareDx, Inc CDNA 4.29%
Beam Therapeutics Inc. BEAM 4.10%
Adaptive Biotechnologies Corporation ADPT 3.82%
Twist Bioscience Corporation TWST 3.75%
Ginkgo Bioworks Holdings, Inc. DNA 3.69%
View More Holdings


Ex-Dividend Amount Pay Date
Dec 29, 2021 $0.38239 Dec 31, 2021
Dec 29, 2020 $0.42557 Dec 31, 2020
Dec 27, 2019 $1.05395 Dec 31, 2019
Dec 27, 2018 $0.26999 Dec 31, 2018
Dec 27, 2017 $0.19272 Dec 29, 2017
Full Dividend History


Get Benefits From Innovator ACCD in Health Tech ETF ARKG

For all the concerns surrounding tech investments over the last year, with mega-cap tech names like Amazon (AMZN) and Meta (META) being the poster children for the broad market selloff, biotech remain...

1 week ago - ETF Trends

4 Sectors & Their ETFs Returning Double-Digits to Start 2023

Wall Street has been showing immense strength to start 2023. These sectors and their ETFs have returned double-digit returns to start 2023.

1 week ago - Zacks Investment Research

Best ETF Areas of Last Week

Wall Street was pretty upbeat last week due to cooling inflation.

2 weeks ago - Zacks Investment Research

EXAS Nears Key Buy Signal in Active Biotech ETF ARKG

There are a lot of reasons to be skeptical of tech investing right now since last year's broad market selloff — just how far is the Fed planning to go with rising rates this year, anyway? Still, there...

2 weeks ago - ETF Trends

Why Now Could Be Time to Buy No Cap Gain ARK Strats

Ready for the new year? It wouldn't be surprising for most ETF investors to be excited to put 2022 in the rear view.

Other symbols: ARKK
1 month ago - ETF Trends

Top-Read Disruptive Technology Stories of 2022

2022 has been a wild year for markets, from Russia's invasion of Ukraine to the Fed's dedicated rate hike campaign. That hasn't stopped the world from innovating, though, with firms in areas from biot...

Other symbols: ARKK
1 month ago - ETF Trends

ARK Continues Contrarian Plays in ETFs TSLA, COIN, VERV

ARK Invest and CEO Cathie Wood have once again bought the dip on firms the company believes have long term potential to be real innovators, adding shares from Tesla (TSLA), Coinbase (COIN), and Verve ...

Other symbols: ARKQARKW
1 month ago - ETF Trends

Gene Editing Stock in ARKG Gets Buy Rating

2022 hasn't been a great year for all kinds of tech stocks, and certainly biotech has taken its fair share of lumps as interest rates have continued to dry up funding. That hasn't stopped the innovati...

1 month ago - ETF Trends

Why a Biotech ETF Might Cure Your Portfolio in 2023

While the headlines have focused on a crypto winter, it hasn't exactly been an easy year for biotech. The sector that blossomed amid a global pandemic has struggled with the pandemic easing and rates ...

1 month ago - ETF Trends

Why This Biotech Firm is the Top Weight in ARKG

You may have missed it over Thanksgiving week, but there's reason to be excited about at least one biotech firm on the market. Exact Sciences Corp (EXAS) was recently the subject of positive attention...

2 months ago - ETF Trends

ARK Completes Move to Florida With Broad Research Team

ARK Invest, which manages $14 billion in ETF assets primarily through active, disruptive technology ETFs, moved headquarters last week to Tampa/St. Petersburg, Florida, from New York. The firm runs so...

Other symbols: ARKKARKW
2 months ago - ETF Trends

Biotech Earnings, Market Leap Boost ARKG Potential

This week's soft CPI print has sent the stock market into a flurry of positivity, hitting multi-year highs on Thursday as investor optimism leaped forward.

Other symbols: ARKK
2 months ago - ETF Trends

As Flu Season Consumers Prefer Telehealth, Watch ARKG

Telehealth options remain very popular with consumers for routine appointments, according to a recent survey, preferred to in-person options for routine care.

3 months ago - ETF Trends

ARKG Holding PacBio's 1-Month Returns Top 48%

ARK Genomic Revolution ETF (ARKG) holding Pacific Biosciences (PACB) opened lower on Monday but is still posting one-month returns topping 48%.  Shares of Pacific Biosciences traded up around 16% last...

3 months ago - ETF Trends

ARKG Holding Senti Biosciences Increases 22% Thursday as Markets Rally

U.S. equities across all sectors are rebounding Thursday following the release of a hotter-than-expected inflation report.  After recent volatility, shares of Senti Biosciences have increased nearly 2...

3 months ago - ETF Trends

ARKK Takes in Nearly Half Billion in September Flows

The ARK Innovation ETF (ARKK) accreted nearly half a billion dollars from investors in September. ARK Invest's flagship fund saw $441 million in net inflows in September, bringing the year-to-date net...

4 months ago - ETF Trends

Positive Sentiment in Biotech Intensifies, Add ARKG

Last week saw significant volatility. However, positive sentiment intensified throughout the biotech space, propelled by favorable legislation and encouraging trial data.

4 months ago - ETF Trends

ARK Changes Management on Passive ETF Lineup

ARK Invest has shaken up the management of its passive ETF offerings by removing CIO Cathie Woods from the day-to-day management of the funds.

4 months ago - ETF Trends

ARKG Offers Exposure to Advancements in Synthetic Biology

New advances in synthetic biology uncovers lucrative investment opportunities for advisors.

4 months ago - ETF Trends

Shares of Signify Health Propelled by Buyout Prospects

Shares of Signify Health (SGFY) have continued to trade up on rumors of CVS Health Corp's (CVS) interest in acquiring the company. Signify Health is exploring strategic alternatives, including a sale,...

5 months ago - ETF Trends

Opportunities Emerge From Rapid Cost Declines in Gene Editing and Synthesis

The rapid cost declines associated with gene editing and gene synthesis are turbo-charging scientific creativity, enabling the testing of hypotheses that, until now, have been cost-prohibitive, ARK In...

5 months ago - ETF Trends

ARKG Holding Butterfly Network Increases 127% in Past Month

Biotech stocks got crushed in the first half of the year as a risk-off sentiment emerged and the growthiest segments of the market were punished, but have rebounded in recent months, with some compani...

6 months ago - ETF Trends

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

6 months ago - Zacks Investment Research

ARKG Top Holding Signify Reported to Be Acquisition Target by CVS

CVS Health Corp (CVS) is seeking to buy Signify Health Inc. (SGFY) as it looks to expand in-home health services, the Wall Street Journal reported on Sunday, citing sources. Signify Health is explorin...

6 months ago - ETF Trends

Investors Flocked to ARKK and ARKG in July as Growth Rebounded

Investors reinstated their positions in the growthiest segments of the market in July. After U.S. equities posted their worst first-half performance since 1970 as inflation concerns, Fed rate hikes, a...

Other symbols: ARKK
6 months ago - ETF Trends